These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35802687)

  • 1. Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis.
    Godolphin PJ; Fisher DJ; Berry LR; Derde LPG; Diaz JV; Gordon AC; Lorenzi E; Marshall JC; Murthy S; Shankar-Hari M; Sterne JAC; Tierney JF; Vale CL
    PLoS One; 2022; 17(7):e0270668. PubMed ID: 35802687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.
    ; Shankar-Hari M; Vale CL; Godolphin PJ; Fisher D; Higgins JPT; Spiga F; Savovic J; Tierney J; Baron G; Benbenishty JS; Berry LR; Broman N; Cavalcanti AB; Colman R; De Buyser SL; Derde LPG; Domingo P; Omar SF; Fernandez-Cruz A; Feuth T; Garcia F; Garcia-Vicuna R; Gonzalez-Alvaro I; Gordon AC; Haynes R; Hermine O; Horby PW; Horick NK; Kumar K; Lambrecht BN; Landray MJ; Leal L; Lederer DJ; Lorenzi E; Mariette X; Merchante N; Misnan NA; Mohan SV; Nivens MC; Oksi J; Perez-Molina JA; Pizov R; Porcher R; Postma S; Rajasuriar R; Ramanan AV; Ravaud P; Reid PD; Rutgers A; Sancho-Lopez A; Seto TB; Sivapalasingam S; Soin AS; Staplin N; Stone JH; Strohbehn GW; Sunden-Cullberg J; Torre-Cisneros J; Tsai LW; van Hoogstraten H; van Meerten T; Veiga VC; Westerweel PE; Murthy S; Diaz JV; Marshall JC; Sterne JAC
    JAMA; 2021 Aug; 326(6):499-518. PubMed ID: 34228774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis.
    Albuquerque AM; Eckert I; Tramujas L; Butler-Laporte G; McDonald EG; Brophy JM; Lee TC
    Clin Microbiol Infect; 2023 Jan; 29(1):13-21. PubMed ID: 35863630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis.
    Zeraatkar D; Cusano E; Martínez JPD; Qasim A; Mangala S; Kum E; Bartoszko JJ; Devji T; Agoritsas T; Guyatt G; Izcovich A; Khamis AM; Lamontagne F; Rochwerg B; Vandvik P; Brignardello-Petersen R; Siemieniuk RAC
    BMJ Med; 2022; 1(1):e000036. PubMed ID: 36936570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.
    ; Sterne JAC; Murthy S; Diaz JV; Slutsky AS; Villar J; Angus DC; Annane D; Azevedo LCP; Berwanger O; Cavalcanti AB; Dequin PF; Du B; Emberson J; Fisher D; Giraudeau B; Gordon AC; Granholm A; Green C; Haynes R; Heming N; Higgins JPT; Horby P; Jüni P; Landray MJ; Le Gouge A; Leclerc M; Lim WS; Machado FR; McArthur C; Meziani F; Møller MH; Perner A; Petersen MW; Savovic J; Tomazini B; Veiga VC; Webb S; Marshall JC
    JAMA; 2020 Oct; 324(13):1330-1341. PubMed ID: 32876694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
    ; Gordon AC; Mouncey PR; Al-Beidh F; Rowan KM; Nichol AD; Arabi YM; Annane D; Beane A; van Bentum-Puijk W; Berry LR; Bhimani Z; Bonten MJM; Bradbury CA; Brunkhorst FM; Buzgau A; Cheng AC; Detry MA; Duffy EJ; Estcourt LJ; Fitzgerald M; Goossens H; Haniffa R; Higgins AM; Hills TE; Horvat CM; Lamontagne F; Lawler PR; Leavis HL; Linstrum KM; Litton E; Lorenzi E; Marshall JC; Mayr FB; McAuley DF; McGlothlin A; McGuinness SP; McVerry BJ; Montgomery SK; Morpeth SC; Murthy S; Orr K; Parke RL; Parker JC; Patanwala AE; Pettilä V; Rademaker E; Santos MS; Saunders CT; Seymour CW; Shankar-Hari M; Sligl WI; Turgeon AF; Turner AM; van de Veerdonk FL; Zarychanski R; Green C; Lewis RJ; Angus DC; McArthur CJ; Berry S; Webb SA; Derde LPG
    N Engl J Med; 2021 Apr; 384(16):1491-1502. PubMed ID: 33631065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality Rates Among Hospitalized Patients With COVID-19 Infection Treated With Tocilizumab and Corticosteroids: A Bayesian Reanalysis of a Previous Meta-analysis.
    Albuquerque AM; Tramujas L; Sewanan LR; Williams DR; Brophy JM
    JAMA Netw Open; 2022 Feb; 5(2):e220548. PubMed ID: 35226077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis.
    Yu SY; Koh DH; Choi M; Ryoo S; Huh K; Yeom JS; Yoon YK
    Emerg Microbes Infect; 2022 Dec; 11(1):1154-1165. PubMed ID: 35343397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Clin Rheumatol; 2018 Jun; 37(6):1471-1479. PubMed ID: 29404725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
    Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T
    Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19.
    Khan FA; Stewart I; Fabbri L; Moss S; Robinson K; Smyth AR; Jenkins G
    Thorax; 2021 Sep; 76(9):907-919. PubMed ID: 33579777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of tocilizumab, sarilumab, and sirukumab in comparison with adalimumab as monotherapy in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Sung YK; Lee YH
    Int J Clin Pharmacol Ther; 2021 Sep; 59(9):618-626. PubMed ID: 34281633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic corticosteroids for the treatment of COVID-19.
    Wagner C; Griesel M; Mikolajewska A; Mueller A; Nothacker M; Kley K; Metzendorf MI; Fischer AL; Kopp M; Stegemann M; Skoetz N; Fichtner F
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014963. PubMed ID: 34396514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
    Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choosing immunomodulating therapies for the treatment of COVID-19: recommendations based on placebo-controlled trial evidence.
    Sweeney DA; Lobo SM; Póvoa P; Kalil AC
    Clin Microbiol Infect; 2024 May; 30(5):611-618. PubMed ID: 38182048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial.
    Sivapalasingam S; Lederer DJ; Bhore R; Hajizadeh N; Criner G; Hosain R; Mahmood A; Giannelou A; Somersan-Karakaya S; O'Brien MP; Boyapati A; Parrino J; Musser BJ; Labriola-Tompkins E; Ramesh D; Purcell LA; Gulabani D; Kampman W; Waldron A; Ng Gong M; Saggar S; Sperber SJ; Menon V; Stein DK; Sobieszczyk ME; Park W; Aberg JA; Brown SM; Kosmicki JA; Horowitz JE; Ferreira MA; Baras A; Kowal B; Thomas DiCioccio A; Akinlade B; Nivens MC; Braunstein N; Herman GA; Yancopoulos GD; Weinreich DM
    Clin Infect Dis; 2022 Aug; 75(1):e380-e388. PubMed ID: 35219277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of interleukin-6 receptor antagonists in adult patients admitted to intensive care unit with COVID-19: A systematic review and
    Peng R; Yang T; Tong Y; Wang J; Zhou H; Yang M; Zhu J; Yang L; Shi Z; Liu Y
    Prev Med Rep; 2023 Aug; 34():102276. PubMed ID: 37309358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.